176 related articles for article (PubMed ID: 27068405)
1. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
[No Abstract] [Full Text] [Related]
2. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
3. Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.
Hinze A; Rinke J; Hochhaus A; Ernst T
Ann Hematol; 2021 Feb; 100(2):581-584. PubMed ID: 32577845
[No Abstract] [Full Text] [Related]
4. Changes in allele frequencies of
Nooruddin Z; Miltgen N; Wei Q; Schowinsky J; Pan Z; Tobin J; Purev E; Gutman JA; Robinson W; Pollyea DA
Haematologica; 2017 May; 102(5):e207-e209. PubMed ID: 28209656
[No Abstract] [Full Text] [Related]
5. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
6. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
7. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
[No Abstract] [Full Text] [Related]
8. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
9. Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for
Ye P; Lin Q; Jin M; Gu X; Lu Y
Turk J Haematol; 2023 Feb; 40(1):73-74. PubMed ID: 36510384
[No Abstract] [Full Text] [Related]
10. Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.
Touw IP; Beekman R
Haematologica; 2013 Oct; 98(10):1490-2. PubMed ID: 24091926
[No Abstract] [Full Text] [Related]
11. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
12. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
13. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of multiple myeloma and a CSF3R-mutated myeloid neoplasm.
Stewart W; Hinton R; Bain BJ
Am J Hematol; 2021 Nov; 96(11):1539-1540. PubMed ID: 34028856
[No Abstract] [Full Text] [Related]
15. Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation.
Druhan LJ; McMahon DP; Steuerwald N; Price AE; Lance A; Gerber JM; Avalos BR
Blood; 2016 Oct; 128(16):2097-2099. PubMed ID: 27581359
[No Abstract] [Full Text] [Related]
16. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.
Szuber N; Finke CM; Lasho TL; Elliott MA; Hanson CA; Pardanani A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):21. PubMed ID: 29449543
[No Abstract] [Full Text] [Related]
17. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
Duployez N; Willekens C; Plo I; Marceau-Renaut A; de Botton S; Fenwarth L; Boyer T; Huet G; Nibourel O; Rose C; Nelken B; Quesnel B; Preudhomme C
Blood; 2019 Dec; 134(26):2414-2416. PubMed ID: 31697825
[No Abstract] [Full Text] [Related]
18. [Chronic neutrophilic leukemia with CSF3R mutation and concurrent multiple myeloma: one case report].
He M; Zhao XC; Bai H
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1052. PubMed ID: 32023742
[No Abstract] [Full Text] [Related]
19. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
20. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
Stoner RC; Press RD; Maxson JE; Tyner JW; Dao KT
Leukemia; 2020 Jun; 34(6):1684-1688. PubMed ID: 31844143
[No Abstract] [Full Text] [Related]
[Next] [New Search]